RESPIVERT LTD.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.respivert.com
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153
Phase 1
Terminated
- Conditions
- AsthmaHealthy Volunteers
- Interventions
- Drug: RV6153 14 day repeat doseDrug: RV6153 single doseDrug: RV6153 28 day repeat doseDrug: RV6153 matching placebo single doseDrug: RV6153 matching placebo 14 day repeat doseDrug: RV6153 matching placebo 28 day repeat dose
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Respivert Ltd
- Target Recruit Count
- 55
- Registration Number
- NCT02517359
Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers
Completed
- Conditions
- AsthmaCOPD
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- Respivert Ltd
- Target Recruit Count
- 25
- Registration Number
- NCT02490358
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: RV1729 28 day repeat doseDrug: RV1729 matching placebo 28 day repeat dose
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2015-07-02
- Lead Sponsor
- Respivert Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT02140346
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days
Phase 1
Completed
- Conditions
- Healthy VolunteersAsthma
- Interventions
- Drug: RV1729 28 day repeat doseDrug: RV1729 14 day repeat doseDrug: RV1729 single doseDrug: RV1729 matching placebo 28 day repeat doseDrug: RV1729 matching placebo 14 day repeat doseDrug: RV1729 matching placebo single dose
- First Posted Date
- 2014-05-16
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Respivert Ltd
- Target Recruit Count
- 49
- Registration Number
- NCT02140320
Safety, Tolerability and Pharmacokinetics (PK) of RV1162 in Healthy Subjects and COPD Patients
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)Healthy Volunteers
- Interventions
- Drug: RV1162 single doseDrug: RV1162 matching placebo single dose
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2014-11-20
- Lead Sponsor
- Respivert Ltd
- Target Recruit Count
- 78
- Registration Number
- NCT01970618
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729
Phase 1
Completed
- Conditions
- AsthmaHealthy Volunteers
- Interventions
- Drug: RV1729 single doseDrug: RV1729 matching placebo single dose
- First Posted Date
- 2013-03-18
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- Respivert Ltd
- Target Recruit Count
- 63
- Registration Number
- NCT01813084
Sample Collection in Smoking Asthma
Completed
- Conditions
- Asthma
- First Posted Date
- 2012-08-31
- Last Posted Date
- 2013-01-08
- Lead Sponsor
- Respivert Ltd
- Target Recruit Count
- 23
- Registration Number
- NCT01676467
A Study to Investigate the Safety and Tolerability of a New Inhaled Formulation of RV568 in Healthy Volunteers
Phase 1
Completed
- Conditions
- COPDHealthy Volunteers
- Interventions
- Drug: RV568 single doseDrug: RV568 repeat doseDrug: RV568 matching placebo single doseDrug: RV568 matching placebo repeat dose
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- Respivert Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT01661244
A Study to Investigate How Safe and Well Tolerated RV568 is in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-11-21
- Last Posted Date
- 2012-05-03
- Lead Sponsor
- Respivert Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT01475292
- Locations
- 🇬🇧
Quintiles Drug Research Unit at Guy's Hospital, London, United Kingdom
🇬🇧Medicines Evaluation Unit (MEU), Manchester, United Kingdom
Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis
- First Posted Date
- 2010-10-29
- Last Posted Date
- 2010-12-06
- Lead Sponsor
- Respivert Ltd
- Target Recruit Count
- 75
- Registration Number
- NCT01230619
- Locations
- 🇦🇹
Institute for Allergy Research, Vienna Challenge Chamber, Vienna, Austria
© Copyright 2025. All Rights Reserved by MedPath